NEWS & EVENTS

Latest news and upcoming events

Ysios Capital ESG Report
20 Nov 2024

Ysios Capital ESG Report

Upcoming events

  • Bio-Neuroscience
    25 - 27 February 2025
    Amsterdam

    download

  • 18th Annual European Life Sciences CEO Forum
    26 - 27 February 2025
    Zurich

    download

  • Redefining Early Stage of Investment (RESI)
    1 April 2025
    Barcelona

    download
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy<
20 Feb 2025

Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy

The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with drug-resistant mesial temporal lobe epilepsy
NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires<
20 Feb 2025

NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires

Topline data from SEFA-1024 Phase 2a clinical trial in SHTG expected in 3Q 2025
Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types<
19 Feb 2025

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types

Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on eliminating hard-to-treat resistant cancer cells
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria<
04 Feb 2025

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025
SparingVision advances PRODYGY trial into Phase II following positive DSMB recommendation<
21 Jan 2025

SparingVision advances PRODYGY trial into Phase II following positive DSMB recommendation

DSMB confirms favorable safety profile of SPVN06 across all three doses in patients with severe advanced rod-cone dystrophy (RCD)(n=9)
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension<
08 Jan 2025

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Estimated 54 million people suffer from obstructive sleep apnea in the U.S.

Anaconda Biomed Appoints Trent Reutiman New CEO<
07 Jan 2025

Anaconda Biomed Appoints Trent Reutiman New CEO

Seasoned Medtech Executive to Expand Company Presence Into U.S.
Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval<
07 Jan 2025

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia<
17 Dec 2024

Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia

Clinical trial in patients anticipated to begin in 2025
SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease<
12 Dec 2024

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

Phase 1/2 ASTRA study set to begin in the first half of 2025.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

rabbywallet offers a seamless, secure solution for managing digital assets. With its intuitive design, it ensures fast transactions and robust security for all your cryptocurrency needs.